251 related articles for article (PubMed ID: 2685653)
1. Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Chase TN; Baronti F; Fabbrini G; Heuser IJ; Juncos JL; Mouradian MM
Neurology; 1989 Nov; 39(11 Suppl 2):7-10; discussion 19. PubMed ID: 2685653
[TBL] [Abstract][Full Text] [Related]
2. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Hoey M; Kutt H; McDowell FH
Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
[TBL] [Abstract][Full Text] [Related]
3. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
Chase TN; Engber TM; Mouradian MM
Neurology; 1994 Jul; 44(7 Suppl 6):S15-8. PubMed ID: 7519334
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Parkinson's disease.
Lieberman A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
[TBL] [Abstract][Full Text] [Related]
5. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
Verhagen Metman L
Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
[TBL] [Abstract][Full Text] [Related]
6. Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias.
López-Ariztegui N; Arévalo MA; de Ceballos ML; Grandas F
Clin Neuropharmacol; 2009; 32(6):321-5. PubMed ID: 19667975
[TBL] [Abstract][Full Text] [Related]
7. A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Cedarbaum JM; Kutt H; McDowell FH
Neurology; 1989 Nov; 39(11 Suppl 2):38-44; discussion 59. PubMed ID: 2586762
[TBL] [Abstract][Full Text] [Related]
8. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
[TBL] [Abstract][Full Text] [Related]
9. New concepts in the treatment of Parkinson's disease.
Ahlskog JE; Wilkinson JM
Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
[TBL] [Abstract][Full Text] [Related]
10. Levodopa/carbidopa/entacapone in Parkinson's disease.
Seeberger LC; Hauser RA
Expert Rev Neurother; 2009 Jul; 9(7):929-40. PubMed ID: 19589043
[TBL] [Abstract][Full Text] [Related]
11. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of sustained dopaminergic stimulation.
Stocchi F; Patsalos PN; Berardelli A; Barbato L; Bonamartini A; Manfredi M; Ruggieri S
Clin Neuropharmacol; 1994; 17 Suppl 2():S7-13. PubMed ID: 9358190
[TBL] [Abstract][Full Text] [Related]
13. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Deleu D; Jacques M; Michotte Y; Ebinger G
Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease: making the diagnosis, selecting drug therapies.
Scharre DW; Mahler ME
Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845
[TBL] [Abstract][Full Text] [Related]
15. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Chase TN
Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
[TBL] [Abstract][Full Text] [Related]
16. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
[TBL] [Abstract][Full Text] [Related]
17. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Parkinson's disease. From theory to practice.
Ahlskog JE
Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
[TBL] [Abstract][Full Text] [Related]
19. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
20. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
